Literature DB >> 19838313

PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.

Yanqing Sun1, Peter B Gilbert, Ian W McKeague.   

Abstract

For time-to-event data with finitely many competing risks, the proportional hazards model has been a popular tool for relating the cause-specific outcomes to covariates [Prentice et al. Biometrics34 (1978) 541-554]. This article studies an extension of this approach to allow a continuum of competing risks, in which the cause of failure is replaced by a continuous mark only observed at the failure time. We develop inference for the proportional hazards model in which the regression parameters depend nonparametrically on the mark and the baseline hazard depends nonparametrically on both time and mark. This work is motivated by the need to assess HIV vaccine efficacy, while taking into account the genetic divergence of infecting HIV viruses in trial participants from the HIV strain that is contained in the vaccine, and adjusting for covariate effects. Mark-specific vaccine efficacy is expressed in terms of one of the regression functions in the mark-specific proportional hazards model. The new approach is evaluated in simulations and applied to the first HIV vaccine efficacy trial.

Entities:  

Year:  2009        PMID: 19838313      PMCID: PMC2762218          DOI: 10.1214/07-AOS554

Source DB:  PubMed          Journal:  Ann Stat        ISSN: 0090-5364            Impact factor:   4.028


  9 in total

Review 1.  Challenges and opportunities for development of an AIDS vaccine.

Authors:  G J Nabel
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

Review 2.  Clinical trials of HIV vaccines.

Authors:  Barney S Graham
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

3.  Tests for comparing mark-specific hazards and cumulative incidence functions.

Authors:  Peter B Gilbert; Ian W McKeague; Yanqing Sun
Journal:  Lifetime Data Anal       Date:  2004-03       Impact factor: 1.588

4.  A nonidentifiability aspect of the problem of competing risks.

Authors:  A Tsiatis
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

5.  The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.

Authors:  Peter B Gilbert; Ian W McKeague; Yanqing Sun
Journal:  Biostatistics       Date:  2007-08-17       Impact factor: 5.899

6.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

7.  Statistical analysis of quality of life data in cancer clinical trials.

Authors:  M Olschewski; M Schumacher
Journal:  Stat Med       Date:  1990-07       Impact factor: 2.373

8.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

9.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

  9 in total
  18 in total

1.  Invited commentary: Evaluating vaccination programs using genetic sequence data.

Authors:  M Elizabeth Halloran; Edward C Holmes
Journal:  Am J Epidemiol       Date:  2009-11-12       Impact factor: 4.897

2.  Profile local linear estimation of generalized semiparametric regression model for longitudinal data.

Authors:  Yanqing Sun; Liuquan Sun; Jie Zhou
Journal:  Lifetime Data Anal       Date:  2013-03-08       Impact factor: 1.588

3.  Mark-specific hazard ratio model with missing multivariate marks.

Authors:  Michal Juraska; Peter B Gilbert
Journal:  Lifetime Data Anal       Date:  2015-10-28       Impact factor: 1.588

4.  Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark.

Authors:  Yanqing Sun; Mei Li; Peter B Gilbert
Journal:  Comput Stat Data Anal       Date:  2014-12-03       Impact factor: 1.681

5.  Estimation of Stratified Mark-Specific Proportional Hazards Models under Two-Phase Sampling with Application to HIV Vaccine Efficacy Trials.

Authors:  Guangren Yang; Yanqing Sun; Li Qi; Peter B Gilbert
Journal:  Stat Biosci       Date:  2016-10-27

6.  Semiparametric modeling and estimation of the terminal behavior of recurrent marker processes before failure events.

Authors:  Kwun Chuen Gary Chan; Mei-Cheng Wang
Journal:  J Am Stat Assoc       Date:  2017-05-03       Impact factor: 5.033

7.  Mark-specific additive hazards regression with continuous marks.

Authors:  Dongxiao Han; Liuquan Sun; Yanqing Sun; Li Qi
Journal:  Lifetime Data Anal       Date:  2016-05-11       Impact factor: 1.588

8.  Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.

Authors:  M Juraska; P B Gilbert
Journal:  Biometrics       Date:  2013-02-19       Impact factor: 2.571

9.  Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials.

Authors:  Peter B Gilbert; Yanqing Sun
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2015-01-01       Impact factor: 1.864

10.  A Hybrid Approach for the Stratified Mark-Specific Proportional Hazards Model with Missing Covariates and Missing Marks, with Application to Vaccine Efficacy Trials.

Authors:  Yanqing Sun; Li Qi; Fei Heng; Peter B Gilbert
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2020-05-22       Impact factor: 1.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.